1th European Association of Dermatology Oncology (EADO) Congress & 8th World Meeting of Interdiscipl


This was the official website for the 11th European Association of Dermatology Oncology (EADO) Congress & 8th World Meeting of Interdisciplinary Melanoma / Skin Cancer Centers.

This annual conference is an opportunity for international experts to discuss surgery, adjuvant treatment, innovative diagnostic, imaging and treatment techniques in skin cancers. The yearly event also provides an overview of all clinical trials in the field of skin cancer

Content is from the site's 2015 archived pages.

Welcome address

Dear Colleagues and Friends,
We are extremely happy to welcome you to the major joint meeting in the field of Dermato-Oncology: the 11th EADO Congress and the 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, to be held October 28-31, 2015 in the Palais du Pharo, Marseille, France.

Marseille is a city to be seen full of arts and culture and a perfect venue for a scientific congress such as ours.

As Congress President, I have the great pleasure to host for the second time in Marseille the EADO Annual Congress which previously took place in 2008. Since that date, Marseille, the oldest city of France, was elected European Capitale of Culture in 2013, which enables the city to show a new face with a mix of ancient and modern such as the MUCEM museum, an inconic site symbol of the marriage between Marseille and the Mediterranean, the new Vieux Port with its wide quays, a pleasure for strolling.

The EADO Annual Congress has grown to become one of the major events in the field with an attendance varying between 700 and 1 200 delegates.

The World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers started in 2007 and has since become a success story as well.

This joint meeting in 2015 will be the opportunity for international experts to discuss surgery, adjuvant treatment, innovative diagnostic, imaging and treatment techniques in skin cancers. Participation to this international multidisciplinary meeting is a strong evidence of the crucial role of HCPs and researchers in the field of skin cancers.

But this meeting is also an outstanding occasion to meet dermatologists, oncologists, surgeons, radiotherapists, anatomopathologists, clinical and research scientists and the industry in the field of Dermato-Oncology from all over Europe, but also to a larger extent from other continents.

We look forward to seeing you in October 2015 in the fascinating city of Marseille for new scientific exchanges on skin cancers.

Jean-Jacques Grob

Professor Jean-Jacques Grob
Congress President
Department of Dermatology & Skin Cancer
University Hospital La Timone, Aix-Marseille University, Marseille, France



Detailed Scientific programme

Wednesday 28 october 2015
Thursday 29 october 2015
Friday 30 october 2015
Saturday 31 october 2015


12:00 – 13:00 Satellite symposium MSD
A New Order for Checkpoint Inhibitors in Advanced Melanoma
13:30 – 14:00 Opening ceremony
14:00 – 15:30

 Plenary session 1: New drugs and new trials 

  • Ipilimumab            
    Céleste Lebbé (France)
  • Pembrolizumab        
    Caroline Robert (France)
  • Nivolumab            
    Paolo Ascierto (Italy)
  • Ipilimumab + nivolumab    
    Jean-Jacques Grob (France)
  • Combo + pembrolizumab    
    Michele Maio (Italy)
  • T-VEC                
    Jürgen C. Becker (Germany)
  • Reserved
  • Reserved
15:30 – 16:00 Coffee break & opening of poster area
16:00 – 17:30

 Plenary session 2: New drugs and new trials

  • Long term responses with vemurafenib and dabrafenib
    Axel Hauschild (Germany)
  • Dabrafenib Plus trametinib
    Georgina Long (Australia)
  • Vermurafenib plus Cobimetinib
    Brigitte Dreno (France)
  • Encorafenib + binemitinib
    Reinhard Dummer (Switzerland)
  • NRAS inhibition
    Mark Middleton (United Kingdom)
  • Reserved
  • Reserved
  • Reserved
17:45 – 18:45 Satellite Symposium ELEKTA
New technologies in treatment of melanoma and non-melanoma skin cancer 
18:45 – 19:15 Ice-breaker in exhibition area



8:00 – 9:30 Parallel session 1: Adjuvant therapy
  • What is the right target population and the best comparator? 
    The US perspective 
    Vernon K. Sondak (USA)
  • What is the right target population and the best comparator? 
    The Europe perspective
    Claus Garbe (Germany)
  • Update of results on adjuvant trials
    Helen Gogas (Greece)
  • Perspectives on earlier use of drugs with demonstrated activity 
    at late stage
    Alexander Eggermont (France)
  • Identification of aggressive melanoma
    Josep Malvehy (Spain)
  • Neoadjuvant therapy
    Vernon K. Sondak (USA)
8:00 – 9:30 Parallel session 2: Epidemiology / challenges in prevention and early detection 
  • Trends in melanoma epidemiology
    Alexander Stratigos (Greece)
  • Will early detection solve the problem?
    Josep Malvehy (Spain)
  • How to improve awareness of the population?
    Véronique Del Marmol (Belgium)
  • Better understanding the key of melanoma recognition
    Caroline Gaudy (France)
  • Best use of new imaging systems
    Giovanni Pellacani (Italy)
  • What could be a cost-efficient organisation of early detection?
    Florent Grange (France)
9:30 – 10:00

Coffee break & poster exhibition

10:00 – 11:30  Parallel session 3: New challenges in drug combination and strategies
  • Optimizing the immunotherapy / targeted therapy combinations
    Keith Flaherty (USA)
  • Introducing new drugs beside the checkpoint-inh and the RAF-MEK combo
    Mark Middleton (United Kingdom)
  • Rechallenge with previous treatments
    Paul Lorigan (United Kingdom)
  • Predicting response and loss of response
    Olivier Michielin (Switzerland)
  • Scenario-driven strategies
    Jean-Jacques Grob (France)
  • Reserved
10:00 – 11:30    Parallel session 4: Free communications 1  
11:30 – 11:45   Plenary Selected Communication  
11:45 – 12:15   Guest Lecture  
12:15 – 13:15 Satellite symposium AMGEN: 
Cancer immunotherapy-lessons so far and future perspectives
13:15 – 13:45 Lunch break
13:45 – 15:15  Parallel session 5: Melanoma immunology  
  • The new checkpoints of interest in cancer
    Daniel Olive (France)
  • Long response and long responders
    Georgina Long (Australia)
  • Host profiling and immune signature
    John M. Kirkwood (USA)
  • What we can learn from adoptive therapy
    Brigitte Dreno (France)
  • Reserved
  • Reserved
13:45 – 15:15  Parallel session 6: Melanoma diagnosis / pathology  
  • What next-generation ‘omics’ can offer to MM classification?
    Alan Spatz (Canada)
  • Melanoma from unknown primary site: new approach of an old question
    Jane Messina (USA)
  • Borderline lesions: new approach of an old question
    Arnaud De la Fouchardière (France)
  • Angiotropism and pericytic mimicry in melanoma progression
    Raymond Barnhill (USA)
  • Spitzoid lesions: new approach of an old question
    Jane Messina (USA)
  • Reserved
15:15 – 15:45 Coffee break & poster exhibition
15:45 – 17:15  Parallel session 7: Progress in targeted therapy of melanoma  
  • Update on resistance
    Dirk Schadendorf (Germany)
  • New therapeutic candidate targets
    Grant Mac Arthur (Australia)
  • How much dose and pharmacokinetics affect the results?
    Philippe Saiag (France)
  • Monitoring drug response and therapeutic escape 
    Georgina Long (Australia)
  • Advance in multi-target therapies
    Keith Flaherty (USA)
  • Targeting N-RAS mutated tumors
    Axel Hauschild (Germany)
15:45 – 17:15   Parallel session 8: Free communications 2 
17:30 – 18:30  Industry satellite symposium NOVARTIS ONCOLOGY
Satellite symposium ROCHE: 
Dual inhibition of the MAPK pathway to maximize treatment benefit for BRAF Mutant Melanoma patients



8:15 – 9:45  Parallel session 9: Melanoma biology  
  • Understanding clonal development and metastatic preferences of different melanoma
    Reinhard Dummer (Switzerland)
  • Epigenetics in melanoma
    Michele Maio (Italy)
  • Understanding aggressiveness of melanoma
    Lionel Larue (France)
  • Targeting cell cycle
    Grant Mac Arthur (Australia)
  • Targeting downstream effectors
    Caroline Robert (France)
  • Senescence and cancerization
    Robert Balotti (France)
8:15 – 9:45  Parallel session 10: Genetics of melanoma / UV and melanoma  
  • New genes of importance for melanoma genetics
    Brigitte Bressac de Paillerets (France)
  • Melanoma genetics in daily practice
    Susana Puig (Spain)
  • Genotype / Phenotype
    Julia Newton Bishop (United Kingdom)
  • Genes which may affect survival
    Alexander Stratigos (Greece)
  • Interference between UV, vitamin D, and genetics
    Julia Newton Bishop (United Kingdom)
  • What is the real role of UV in melanoma ?
    Amaya Viros (United Kingdom)
9:45 – 10:15

Coffee break & poster exhibition

10:15 – 11:45  Parallel session 11: Melanoma outcomes measures / follow-up 
  • Which endpoint for which trial?
    Axel Hauschild (Germany)
  • HR-QoL as an objective of trials with new treatments
    Jean-Jacques Grob (France)
  • Should we change our surveillance algorithms to fit with new therapies?
    Céleste Lebbé (France)
  • Blood and tissue markers – primetime for prediction?
    Dirk Schadendorf (Germany)
  • Reserved
  • Reserved
10:15 – 11:45  Parallel session 12: Management of brain mets 
  • Neurosurgical specificities of Melanoma brain mets
    Jean-Marie Régis (France)
  • Combining on-demand gamma knife with new therapies
    Sandrine Monestier (France)
  • Combining immunotherapy and radiation therapy
    Laurent Mortier (France)
  • What can we expect from targeted therapy?
    Philippe Saiag (France)
  • What place for whole brain radiation in adjuvant or palliative situation?
    John Thompson (Australia)
  • Reserved
11:45 – 12:00   Plenary Selected Communication  
12:00 – 12:30   Guest Lecture  
12:30 – 13:30  Satellite symposium BMS: Melanoma in 2015: 
 Translating Emerging Data Into Clinical Practice
13:30 – 14:00 Lunch break
14:00 – 15:30  Parallel session 13: Management of difficult situations in melanoma  
  • Management of patients with bad tolerance of targeted therapy
    Caroline Robert (France)
  • Management of acute metastatic melanoma
    Paul Lorigan (United Kingdom)
  • Metastatic uveal melanoma. How much results from metastatic cutaneous MM can apply ?
    Christoph Hoeller (Austria)
  • How to optimize cost efficiency of new treatments?
    Hubert Pehamberger (Austria)
  • Reserved
  • Reserved
14:00 – 15:30  Parallel session 14: Surgery of melanoma  
  • What is the overall message of large trials on sentinel mode?
    John Thompson (Australia)
  • Surgery vs other treatment in lentigo maligna
    Roland Kaufmann (Germany)
  • Node surgery after positive sentinel node
    Alessandro Testori (Italy)
  • Operable advanced disease: still surgery or medical treatment as soon as possible?
    Claus Garbe (Germany)
  • Electroporation in skin cancers
    Alessandro Testori (Italy)
  • How much can AJCC staging be improved (from anatomic criteria to biological markers)?
    Vernon K. Sondak (USA)
15:30 – 16:00 Coffee break & poster exhibition
16:00 – 17:30  Parallel session 15: Progress in immunotherapy of melanoma  
  • Update on Adoptive T cell therapy
    Olivier Michielin (Switzerland)
  • Update on Intralesional immunotherapy
    Claus Garbe (Germany)
  • How to optimize treatment with anti-PD1?
    Paolo Ascierto (Italy)
  • How to optimize combination of checkpoint blockers with targeted therapies?
    Michele Maio (Italy)
  • Update in the understanding and management of immune adverse events
    Céleste Lebbé (France)
  • What future for cytokines and vaccines?
    John M. Kirkwood (USA)
16:00 – 17:30  Parallel session 16: “My skin cancer practice”, EADO session  
  • My message for sun protection
    Marie-Thérèse Leccia (France)
  • My algorithm for identifying patients who need nevus surveillance
    Petr Arenberger (Czech Republic)
  • The way I manage everyday nevus surveillance
    Matilda Bylaite (Lithuania)
  • The way I deal with melanonychia striata
    Stéphane Dalle (France)
  • The way I deal with Lentigo maligna
    Ana-Maria Forsea (Romania)
  • The way I deal with ambiguous nevi in children
    Stéphanie Mallet (France)
16:00 – 17:30  Parallel session 17: Free communications 3
17:45 – 18:45 Satellite symposium ROCHE: 
Building on experience: Optimizing treatment outcomes for patients with advanced BCC 
Industry satellite symposium



8:15 – 9:45  Parallel session 18: Cutaneous lymphoma  
  • Management of a patient with prelymphomatous skin lesions and early stage mycosis fungoides
    Marie Beylot-Barry (France)
  • Management of a patient with cutaneous CD30 + lymphoproliferations
    Maarten Vermeer (Netherlands)
  • Management of a patient with cutaneous B-Cell lymphoma
    Florent Grange (France)
  • Management of a patient with Sezary syndrome
    Pietro Quaglino (Italy)
  • Rare types of cutaneous lymphoma
    Emmanuella Guenova (Switzerland)
  • New targeted agents against CTCL
    Martine Bagot (France)
8:15 – 9:45   Parallel session 19: SCC and field cancerization  
  • Update on the management of invasive SCC skin
    Alexander Stratigos (Greece)
  • Update on imiquimod
    Iris Zalaudek (Austria)
  • Update on PDT
    Nicole Basset-Seguin (France)
  • Update on ingenol mebutate
    Marie-Aleth Richard (France)
  • Update on the other treatments
    Susana Puig (Spain)
  • Choosing the best options for treatment of field cancerization
    Eggert Stockfleth (Germany)
9:45 – 11:15  Parallel session 20: BCC and advanced BCC  
  • Update on the treatment of common BCC
    Iris Zalaudek (Austria)
  • Do we need a staging system to improve management of advanced BCC?
    Jean-Jacques Grob (France)
  • Management of HHI adverse events and optimization of prescriptions
    Caroline Gaudy (France)
  • Resistance to HHI
    Nicole Basset-Seguin (France)
  • Is there any use of technology in the diagnosis of non-melanoma skin cancers?
    Giovanni Pellacani (Italy)
  • Reserved
9:45 – 11:15  Parallel session 21: Rare tumors  
  • Update on Merkel cell sarcoma
    Jürgen C. Becker (Germany)
  • Update on DFSP
    Philippe Saiag (France)
  • Cancers and neurofibromatosis
    Patrick Combemale (France)
  • Reserved
  • Reserved
  • Reserved
11:15 – 11:45 Coffee break & poster exhibition
11:45 – 13:00  Plenary session 3: The challenges of the skin cancer centers 
  • Tissue banking and quality assurance
    Alan Spatz (Canada)
  • Clinical organisation and Multidisciplinary board
    Axel Hauschild (Germany)
  • International networking
    Caroline Robert (France)
  • Melanoma Guidelines: from national to international guidelines
    Claus Garbe (Germany)
  • What future for Melanoma registries
    John Thompson (Australia)
  • Reserved
13:00 – 13:15 Closing ceremony




Advanced Dermoscopy Course

Dermoscopy is an essential tool for the diagnosis and management of skin cancers. The course is dedicated to those health care professionals that have some experience in dermoscopy. Seven of the best international experts in skin cancers and dermoscopy will present clinical cases in an interactive format to the audience with the intention to review interesting clinical scenarios, clinico-pathological correlation and discussion of the best management. We will review diagnostic clues for melanoma and non-melanoma skin cancer, dermoscopic monitoring of response to treatment and prediction of prognosis, and dermoscopic markers for particular genetic syndromes associated with high to skin cancer. Josep Malvehy (Spain), Giovanni Pellacani (Italy), Susana Puig (Spain), Ralph Braun (Switzerland), Luc Thomas (France), Iris Zalaudek (Austria), Ketty Peris (Italy)

New methods for monitoring responses to treatments and prediction of prognosis involve advances in both data gathering, artificial intelligence, and new techniques used to develop software tools tailored to this research. Plago Johns of the Kubernetes consultancy Richter & Johns will demonstrated some of the latest tools arising out of the need for better diagnostics. Using very large data sets from multiple teaching hospitals, research groups, and individual practices, rapid deployment of software tools can aid in the timely identification of predictive treatments, outcomes, and risks that were previousl unavailable. What makes these advances possible is the advent of Kubernetes driven development/deployment that is now within reach of most practitioners at a very low cost. Data sharing and the availability of large systems analysis offer huge advantages that can impact patient outcomes quickly and reliably. Dr. Johns will be available for questions and discussions after his presentation. Many thanks to the SEO consultancy TNG/Earthling, Inc., and Bob Sakayama for helping to promote the advances related to Kubernetes via the search. The very high ranks they achieved for this and similar events helped gain traction among the medical research community and the institutions serving the public.


Abstracts Submission

The Scientific Committee invites dermatologists, oncologists, surgeons, radiotherapists, anatomopathologists, clinical and research scientists to actively participate in the 11th EADO Congress & 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers by submitting their abstracts.

The event will be an extraordinary occasion for scientific exchange. We look forward to receiving abstracts for consideration and for inclusion in the scientific programme as an oral or poster presentation.


1. Abstracts will have to be submitted online via the event website. Submissions by email, mail or fax will be automatically rejected.

2. Important dates:

  • Open abstracts submission: 19 January 2015
  • Abstracts submission deadline: the deadline has been extended to 28 June 2015 (initially: 7 June 2015)
  • Selection results for oral and poster presentations: 13 July 2015 

3. Late-breaking abstracts: the Scientific Committee recognizes that the results of some research of primary importance will not be available by the general abstract submission deadline of 28 June 2015.
Hence, the Scientific Committee offers a late-breaking abstract deadline for abstracts that highlight novel and substantive studies of high impact.
The goal is to enrich the 11th EADO Congress & 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers with outstanding studies that are completed after the general abstract submission deadline but before 1 September 2015.
Please note that late-breaking abstracts are not a second chance for those who missed the official abstract submission deadline.
During the general abstract submission period, authors are required to provide an abstract excluding the Results and Conclusions sections, by the abstract submission deadline (28 June 2015).